These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31669449)

  • 1. Hybrid clinical trials to generate real-world evidence: design considerations from a sponsor's perspective.
    Zhu M; Sridhar S; Hollingsworth R; Chit A; Kimball T; Murmello K; Greenberg M; Gurunathan S; Chen J
    Contemp Clin Trials; 2020 Jul; 94():105856. PubMed ID: 31669449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Evidence: A Primer.
    Dang A
    Pharmaceut Med; 2023 Jan; 37(1):25-36. PubMed ID: 36604368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial designs using real-world data: The changing landscape of the regulatory approval process.
    Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
    Wu J; Wang C; Toh S; Pisa FE; Bauer L
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Evidence-Current Developments and Perspectives.
    Schad F; Thronicke A
    Int J Environ Res Public Health; 2022 Aug; 19(16):. PubMed ID: 36011793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comprehensive Framework for Evaluating the Value Created by Real-World Evidence for Diverse Stakeholders: The Case for Coordinated Registry Networks.
    Gressler LE; Marinac-Dabic D; Resnic FS; Williams S; Yang K; Weichold F; Avila-Tang E; Mack C; Coplan P; Panagiotou OA; Pappas G
    Ther Innov Regul Sci; 2024 Nov; 58(6):1042-1052. PubMed ID: 39060838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics.
    Klonoff DC
    J Diabetes Sci Technol; 2020 Mar; 14(2):345-349. PubMed ID: 30862182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
    Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
    Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
    Webster J; Smith BD
    Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment.
    Timbie JW; Kim AY; Concannon TW
    Value Health; 2021 Dec; 24(12):1792-1798. PubMed ID: 34838277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding Use of Real-World Data and Real-World Evidence to Support Regulatory Decisions on Medical Product Effectiveness.
    Mahendraratnam N; Mercon K; Gill M; Benzing L; McClellan MB
    Clin Pharmacol Ther; 2022 Jan; 111(1):150-154. PubMed ID: 33891318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sources of Safety Data and Statistical Strategies for Design and Analysis: Real World Insights.
    Marchenko O; Russek-Cohen E; Levenson M; Zink RC; Krukas-Hampel MR; Jiang Q
    Ther Innov Regul Sci; 2018 Mar; 52(2):170-186. PubMed ID: 29714518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generate Analysis-Ready Data for Real-world Evidence: Tutorial for Harnessing Electronic Health Records With Advanced Informatic Technologies.
    Hou J; Zhao R; Gronsbell J; Lin Y; Bonzel CL; Zeng Q; Zhang S; Beaulieu-Jones BK; Weber GM; Jemielita T; Wan SS; Hong C; Cai T; Wen J; Ayakulangara Panickan V; Liaw KL; Liao K; Cai T
    J Med Internet Res; 2023 May; 25():e45662. PubMed ID: 37227772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leveraging Real-World Evidence: A Paradigm Shift in Regulation.
    De S; Larson L; Kelly K; Hanson B; Mack CD
    J Orthop Trauma; 2021 Mar; 35(Suppl 1):S13-S16. PubMed ID: 33587541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the ethical and regulatory issues in pragmatic clinical trials.
    Califf RM; Sugarman J
    Clin Trials; 2015 Oct; 12(5):436-41. PubMed ID: 26374676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Evidence in the Real World: Beyond the FDA.
    Krause JH; Saver RS
    Am J Law Med; 2018 May; 44(2-3):161-179. PubMed ID: 30106647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real world evidence: An Indian perspective.
    Dang A; Vallish BN
    Perspect Clin Res; 2016; 7(4):156-160. PubMed ID: 27843789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examining the Use of Real-World Evidence in the Regulatory Process.
    Beaulieu-Jones BK; Finlayson SG; Yuan W; Altman RB; Kohane IS; Prasad V; Yu KH
    Clin Pharmacol Ther; 2020 Apr; 107(4):843-852. PubMed ID: 31562770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of real-world data/evidence in regulatory submissions.
    Song F; Zang C; Ma X; Hu S; Sun Q; Chow SC; Sun H
    Contemp Clin Trials; 2021 Oct; 109():106521. PubMed ID: 34339865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world evidence and product development: Opportunities, challenges and risk mitigation.
    Naidoo P; Bouharati C; Rambiritch V; Jose N; Karamchand S; Chilton R; Leisegang R
    Wien Klin Wochenschr; 2021 Aug; 133(15-16):840-846. PubMed ID: 33837463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.